Skip to content

Surgery Partners, Inc. SGRY Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
UnitedHealth Group logo
UnitedHealth GroupUNH
HCA Healthcare logo
HCA HealthcareHCA
ARD
Ardent Health PartnersARDT
Solventum logo
SolventumSOLV
PACS Group logo
PACS GroupPACS

Other financials

Income statement

See full
Revenue$810.9M+4.5%
Operating income$65.8M+6.3%
Net income-$35.9M+4.8%
EPS (diluted)-$0.28+6.7%

Balance sheet

See full
Cash & equivalents$182.3M-20.5%
Total debt$5.1B+4.6%
Total equity$1.7B-3.0%
Total assets$8.0B+1.2%

Cash flow

See full
Operating cash flow$11.7M+95.0%
CapEx$16.0M-29.5%
Free cash flow-$4.3M+74.3%

Valuation

See full
Market cap$1.99B-49.1%

Profitability

See full
Gross margin23.1%
Operating margin11.8%+1.2pp
Net margin-2.3%-0.9pp
FCF margin6.2%+0.8pp

Returns & leverage

See full
Return on equity-4.4%-1.6pp
Debt / equity+0.2×
Current ratio1.9×0.0×

Where this comes from

Reported directly by Surgery Partners, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Surgery Partners, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Surgery Partners, Inc.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Surgery Partners, Inc.'s common stock, shares authorized (in shares)?
Surgery Partners, Inc. (SGRY) reported common stock, shares authorized (in shares) of $300M in Q1 2026.
How has Surgery Partners, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
Surgery Partners, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $300M to $300M.
What is the long-term trend for Surgery Partners, Inc.'s common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Surgery Partners, Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $300M to $300M.